Scarica l'app Stockscreener
2.52
1.61%
0.04
Alpha Tau Medical Ltd Borsa (DRTS) Ultime notizie
Alpha Tau Medical (NASDAQ:DRTSW) Shares Down 7.4% – Time to Sell? - Defense World
Alpha Tau Receives Fda Approval to Initiate A Trial for Patients with Recurrent Glioblastoma - MarketScreener
Alpha Tau receives FDA approval to start trial for patients with recurrent GBM - TipRanks
Alpha Tau Receives FDA Approval To Initiate A Trial For Patients With Recurrent Glioblastoma - MarketScreener
Alpha Tau Medical Receives FDA Approval for Glioblastoma Trial - TipRanks
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma - GlobeNewswire
Major FDA Approval: Alpha Tau's Revolutionary Brain Cancer Treatment Advances to Human Trials - Stock Titan
Analyzing Vivos Therapeutics (NASDAQ:VVOS) and Alpha Tau Medical (NASDAQ:DRTS) - Defense World
Comprehensive Insights of the Global Vulvar Cancer Market: Key Drivers, Trends, Growth Opportunities, and F... - WhaTech
Alpha Emitter Market Demand, Growth and Future Scope 2025-2032 | - openPR
HC Wainwright Forecasts Lower Earnings for Alpha Tau Medical - Defense World
Pancreatic Cancer Clinical Pipeline | 290+ Companies Advancing the Future of Treatment - openPR.com
Alpha Tau Medical’s (DRTS) Buy Rating Reaffirmed at HC Wainwright - Defense World
Q1 Virtual Investor Summit: On-Demand Presentations Now Live - The Globe and Mail
H.C. Wainwright maintains Buy on Alpha Tau stock, $9 target - Investing.com
H.C. Wainwright maintains Buy on Alpha Tau stock, $9 target By Investing.com - Investing.com UK
Promising Clinical and Regulatory Milestones Drive Buy Rating for Alpha Tau Medical Ltd. - TipRanks
Alpha Tau Medical Faces Uncertain Future Amid Clinical Trial Challenges - TipRanks
Alpha Tau Medical Reports 2024 Earnings and Clinical Progress - TipRanks
Alpha Tau Medical (NASDAQ:DRTSW) Trading Down 2.7% – Time to Sell? - Defense World
Alpha Tau Medical Reports 2024 Financial Results and Advances in Cancer Therapy Trials - TipRanks
Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Alpha Tau's Cancer Therapy Achieves 100% Disease Control Rate in Latest Trials - StockTitan
Alpha Emitter Market to Witness Remarkable Growth with Actinium Pharmaceutical Inc., Alpha Tau Medical Ltd - openPR
U.S. Brain Tumor Market Size & Share | Industry Report 2034 - Grand View Research
March 2025 Penny Stocks To Consider For Growth - Simply Wall St
Alpha Tau Medical to Showcase Alpha DaRT at March Investor Conferences - TipRanks
Alpha Tau to Participate in March Investor Conferences - The Manila Times
Sonodynamic Therapy Shows Promise for Glioblastoma Treatment - Targeted Oncology
Alpha Tau Achieves MDSAP Certification, Boosting Global Expansion Efforts - TipRanks
Alpha Tau Medical Gets Medical Device Single Audit Program Certification -February 24, 2025 at 10:37 am EST - Marketscreener.com
Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification - The Manila Times
Can This New Medical Certification Transform Alpha Tau's Cancer Treatment Rollout? - StockTitan
Locally Advanced Pancreatic Cancer Market to Reach New Heights - openPR
Alpha Tau Medical Ltd. (NASDAQ:DRTS) Short Interest Update - MarketBeat
Alpha Tau Announces FDA Approval of IDE Supplement to - GlobeNewswire
Alpha Tau Medical Gets FDA Approval to Expand DaRT Study in Pancreatic Cancer - Marketscreener.com
Alpha Tau Medical Ltd. Announces FDA Approval of IDE Supplement to Expand Pilot Trial of Alpha DaRT®? to Thirty Patients with Pancreatic Cancer in Two Cohorts, with Locally Advanced or Metastatic Disease - Marketscreener.com
Alpha Tau Gains FDA Approval to Expand Pancreatic Cancer Trial - TipRanks
Major Clinical Trial Expansion: Alpha Tau Doubles Down on Revolutionary Pancreatic Cancer Treatment - StockTitan
Alpha Emitter Market Projected To Witness Massive Growth, - openPR
Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day - GlobeNewswire
Alpha Tau Medical Reports Promising Interim Data and Regulatory Milestones in Cancer Trials - TipRanks
Alpha Tau shares interim data across multiple clinical trials at R&D Update Day - TipRanks
Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials -January 27, 2025 at 09:02 am EST - Marketscreener.com
Alpha Tau's Cancer Therapy Shows Breakthrough Results in Multiple Clinical Trials - StockTitan
Alpha Tau Medical (NASDAQ:DRTSW) Stock Price Up 14.3% – Still a Buy? - Defense World
Short Interest in Alpha Tau Medical Ltd. (NASDAQ:DRTS) Rises By 7.1% - MarketBeat
Takeout news crowns JPM’s winning stocks - biocentury.com
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):